We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


AmpliPhi Announces the Appointment of Baxter Phillips

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AmpliPhi Announces the Appointment of Baxter Phillips"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

AmpliPhi BioSciences Corporation. has announced that it has appointed Baxter Phillips, III, to the newly created position of Vice President, Corporate Strategy and Business Development.

Mr. Phillips has more than 15 years of experience in leading multinational corporate strategy efforts and structuring, negotiating, and executing strategic alliances, licenses and collaborations in the biotechnology and pharmaceutical industry.

Mr. Phillips will lead a variety of corporate and business development initiatives at AmpliPhi. Mr. Phillips will be U.S. based and reports directly to Philip J. Young, President and Chief Executive Officer of AmpliPhi.

“Baxter’s diverse background and successful global experiences in strategy, finance and licensing, will help accelerate AmpliPhi’s corporate initiatives as we continue our progress and growth to become the leading bacteriophage Company developing and delivering novel antibiotic therapies” said Mr. Young.

Before joining AmpliPhi, Mr. Phillips was Director of Business Development at Depomed, Inc. where he led efforts to enter new collaborations with the company’s platform formulation technology.

Additionally, Mr. Phillips was responsible for licensing the company’s product portfolio of both development-stage and marketed products on a global basis, including the U.S, Europe, Japan and Latin America.

Prior to Depomed, Mr. Phillips served as Senior Director, Corporate Development at Osteologix, where he worked directly with Mr. Young for four years as the team developed a novel therapy for osteoporosis, which resulted in a successful global licensing deal with a multinational pharmaceutical company.

Prior to Osteologix, Mr. Phillips was with Insmed, Inc. for ten years where he held a range of leadership positions in research, licensing, finance, investor relations, and sales and marketing.

Mr. Phillips received his MBA from the College of William and Mary and his Bachelor of Science in Biology from Hampden-Sydney College.

Commenting on his appointment Mr. Phillips said: “I am extremely pleased to join Phil and the great team at AmpliPhi in an effort to continue on our mission to be a leader in developing novel antibacterial treatments. As we embark on the age of the post-antibiotic era with ever increasing drug resistance, our mission to find new treatments is critically important to our global stakeholder community, including the millions of individuals not receiving effective antibiotic treatments.”